Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Geetha, P.
- In-Vitro Study of Anthelmintic Activity of Eclipta prostrata (L) y Various Extracts
Abstract Views :271 |
PDF Views:3
Authors
Affiliations
1 Department of Pharmacology, School of Pharmaceutical sciences, Vels University (VISTAS), Chennai, IN
1 Department of Pharmacology, School of Pharmaceutical sciences, Vels University (VISTAS), Chennai, IN
Source
Research Journal of Pharmacy and Technology, Vol 10, No 1 (2017), Pagination: 58-60Abstract
Objective: the present study was conducted to validate in-vitro anthelmintic activity of various extract hexane, ethyl acetate, ethanol, water of eclipta prostrata (l)., aganist pheritima posthuma by petri-dish method. Method: the in-vitro trial for anthelmintic activity of various extract of eclipta prostrata(l)., was conducted on mature live pheritima posthuma by petri-dish method. The extracts were used at the concentration of 5mg, 10mg, and 15mg and observation were made on their viability at room temperature. Results: among the various extract, only ethyl acetate and ethanol have anthelmintic activity. 5mg, 10mg, 15 mg/ml of ethyl acetate have produced paralytic effect at 34minutes minutes, 29 minutes and 20 minutes and mortality was confirmed at 111 minutes, 61 minutes and 46 minutes.5mg, 10mg, 15 mg/ml of ethanol have produced paralytic effect at 27 minutes, 23 minutes and 17 minutes and mortality was confirmed at 83 minutes, 72 minutes and 34 minutes respectively. Conclusion: an anthelmintic has been confirmed as the various extract shows good anthelmintic activity against pheritima posthuma. In the present investigation, the whole plant of eclipta prostrata (l)., was taken up for extensive studies " preliminary phytochemical and pharmacological studies of the whole plant of eclipta prostrata (l)., (asteraceae).Keywords
Eclipta prostrata (L)., Anthelmintic, Pheritima Posthuma, Albendazole, Soxhlet Extraction.
- Assessment of Appropriate use of Antibiotics in Paediatric Department of A Tertiary Care Teaching Hospital
Abstract Views :186 |
PDF Views:1
Authors
Affiliations
1 Dept. of Pharmacy Practice, School of Pharmaceutical Sciences, Vels University (VISTAS), Velannagar, PV Vaithyalingam Road, Pallavaram, Chennai-600117, Tamil Nadu, IN
1 Dept. of Pharmacy Practice, School of Pharmaceutical Sciences, Vels University (VISTAS), Velannagar, PV Vaithyalingam Road, Pallavaram, Chennai-600117, Tamil Nadu, IN
Source
Research Journal of Pharmacy and Technology, Vol 10, No 2 (2017), Pagination: 381-384Abstract
Aim and objective: To determine the appropriate antibiotic therapy in paediatrics and evaluate the appropriateness of antibiotic treatment.
Methods: A prospective study of 9 months duration was carried out from Aug 2015-April 2016. A total 200 prescriptions were collected. The data was collected using specially designed data entry form and appropriateness is assessed with the help of IAP and NICE guidelines.
Results: Out of 200 patients, 14 were in the age group <1 year, 80 were in between 1-3 years of age, 74 were in the age group of 3-8 years and above 8-12 years were 32. Among study population the disease LRTI was the most common diagnosis in 0-1 year (Infant), AGE was the most common diagnosis in the age group 1-3 years, LRTI was mostly found in the age group of 3-8 years and 8-12 years. Significant difference was found in the age group of patient and disease encountered [p= 0.0008]. The third generation cephalosporin, Cefixime (32%) was mostly used, followed by Metronidazole (25%) and Amoxicillin (16%). The Gentamicin(3%) was given to the least patients.
Conclusion: The study concludes that over 200 prescriptions, it was found that most of the antibiotic therapy in the drug regimen is appropriate to the above mentioned guidelines, only slight variation in the drug regimen seen. It shows that the antibiotic therapy in pediatric ward is appropriate to the guidelines.
- A Prospective Observational Study on Assessment of Risk Factor Associated with Diabetic Retinopathy in Patients Diagnosed with Type 2 Diabetes Mellitus in South Indian Population
Abstract Views :157 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science,Technology and Advanced Studies, Pallavaram, Chennai, IN
2 School of Pharmaceutical Sciences, Vels Institute of Science,Technology and Advanced Studies, Pallavaram, Chennai, IN
1 Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science,Technology and Advanced Studies, Pallavaram, Chennai, IN
2 School of Pharmaceutical Sciences, Vels Institute of Science,Technology and Advanced Studies, Pallavaram, Chennai, IN
Source
Research Journal of Pharmacy and Technology, Vol 12, No 2 (2019), Pagination: 595-599Abstract
Objective: Diabetic Retinopathy (DR) appears to be the most common cause of blindness worldwide. The objective of the study was to assess the risk factors that would increase the onset or progression of the microvascular complication caused due to type 2 Diabetes Mellitus. Methods: A prospective observational study was conducted in a tertiary care hospital, Chennai. The enrolled patients based on their inclusion and exclusion criteria were followed and the information collected includes their demographic data and lab investigations such as, Hypertension, HbA1c, and Dyslipedimia. The data observed was analyzed with SPSS V20.0 to find significance among the risk factors of Diabetic Retinopathy. Results: Among the study population of 230, risk factor was analysed for occurrence of Diabetic Retinopathy, Female patient was more affected with Diabetic Retinopathy compared to male 112 and it showed the P - value of 0.001. Most of the people who have Diabetic Retinopathy fall under the age category of 40 to 60 years. The descriptive statistics for age showed the following results Mean ± SD (48.16±10.29) for patients without Diabetic Retinopathy and Mean ± SD (56.24±7.35) for patients with Diabetic Retinopathy. It showed a P-value of 0.004. A significant correlation was seen between the duration of Diabetes Mellitus and the occurrence of Diabetic Retinopathy, showing a P- value of 0.001. Presence of Hypertension also seemed to increase the occurrence of Diabetic Retinopathy, showing a highly significant P-value of 0.001. Presence of Hyperlipidemia had no correlation with the occurrence of Diabetic Retinopathy. A significant level of correlation was seen between the level of glycated haemoglobin and the occurrence of Diabetic Retinopathy showing a P- value of 0.001. Conclusion: Our study concluded that duration of diabetes, presence of hypertension, presence of dyslipedimia and high level of HbA1c has a significant relationship as a risk factor for the onset and progression of Diabetic Retinopathy (DR).Keywords
Risk Factors, Dyslipedimia, Hypertension, HbA1c, Diabetes, Retinopathy.References
- "About diabetes". World Health Organization..Available from: URL:http://www.who.int/mediacentre/factsheets/fs312/en/.
- "Diabetes Fact sheet No 312". WHO. October 2013.
- Shoback, edited by David G. Gardner, Dolores (2011). "Chapter 17". Greenspan's basic & clinical endocrinology (9th ed.). New York: McGraw-Hill Medical. ISBN 0-07-162243-8.
- "Diabetes: Facts And Figures". International Diabetes Federation. N.p., 2017. Web. 4 Mar. 2017.
- "Diabetic retinopathy". Diabetes.co.uk. Retrieved 25 November 2012.
- Kertes PJ, Johnson TM, eds. (2007). Evidence Based Eye Care. Philadelphia, PA: Lippincott Williams & Wilkins. ISBN 0-7817-6964-7.
- Tapp RJ; Shaw JE; Harper CA; et al. (June 2003). "The prevalence of and factors associated with diabetic retinopathy in the Australian population". Diabetes Care. 26 (6): 1731–7. doi:10.2337/diacare.26.6.1731. PMID 12766102.
- International Diabetes Federation: The Diabetes Atlas. 4th edition; 2009.
- Aiello LP, Gardner TW, King GL, Blanken-ship G, Cavallerano JD, Ferris FL, et al. Diabetes Care (technical review). Diabetes Care. 1998; 21:143–56.
- Pugliese G, Solini A, Zoppini G, Fondelli C, Zerbini G, Vedovato M, et al. High prevalence of advanced retinopathy in patients with type 2 diabetes from the Renal Insufficiency and Cardiovascular Events(RIACE) Italian Multicenter Study. Elsevier Diabetes Res Clin Pract. 2012; 98(2):329–37.
- Esteves J, da Rosa CM, Kramer CK, Osowski LE, Milano S, Canani LH: Absence of diabetic retinopathy in a patient who has had diabetes mellitus for 69 years, and inadequate glycemic control: case presentation. Diabetol Metab Syndr. 2009; 1:13.
- Chatziralli, Irini P et al. "Risk Factors Associated With Diabetic Retinopathy In Patients With Diabetes Mellitus Type 2.". BMC Research Notes 3.1. 2010; 153. Web.
- Rani PK, Raman R, Chandrakantan A, Pal SS, Perumal GM, Sharma T: Risk factors for diabetic retinopathy in self-reported rural population with diabetes. J Postgrad Med. 2009; 55:92-96.
- Krishnaiah, Sannapaneni et al. "Risk Factors for Age-Related Macular Degeneration: Findings From The Andhra Pradesh Eye Disease Study In South India". Investigative Opthalmology & Visual Science 46.12 (2005); 4442.
- Pradeepa R, Anitha B, Mohan V, Ganesan A, Rema M: Risk factors for diabetic retinopathy in a South Indian Type 2 diabetic population—the Chennai Urban Rural Epidemiology Study (CURES) Eye Study 4. Diabet Med. 2008; 25:536-542.
- UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998; 352(9131):837–853.
- Krishnamurty U, Steffes MW. Glycohemoglobin: a primary predictor of the development or reversal of complications of diabetes mellitus. Clin Chem. 2001; 47: 1157–65.
- Sabanayagam C, Liew G, Tai ES, Shankar A, Lim SC, Subramaniam T, et al. Relationship between glycated haemoglobin and microvascular complications: is there a natural cut-off point for the diagnosis of diabetes. Diabetologia. 2009 [Epub ahead of print].
- Nakagami T, Kawahara R, Hori S, Omori Y. Glycemic control and prevention of retinopathy in Japanese NIDDM patients. A 10-year follow-up study. Diabetes Care. 1997; 20: 621–2.
- Brow JB, Pedula KL, Summers KH. Diabetes Care. 2003 ;26: 2637–42.
- Anitha B, Sampathkumar R, Balasubramanyam M, Rema M. Advanced glycation index and its association with severity of diabetic retinopathy in type 2 diabetic subjects. J Diabet Complications. 2008; 22:261–6.
- McKay R, McCarty CA, Taylor HR. Diabetic retinopathy in Victoria, Australia: the visual impairment project. Br J Ophthalmol. 2000; 84:865–70.
- Cho NH, Kim TH, Woo SJ, Park KH, Lim S, Cho YM, Park KS, Jang HC, Choi SH: Optimal HbA1c cutoff for detecting diabetic retinopathy. Acta Diabetol. 2013. doi:10.1007/s00592-013-0452-3.
- Aiello LP, Cahill MT, Wong JS: Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol. 2001; 132:760–776.
- Cheung N, Mitchell P, Wong TY: Diabetic retinopathy. Lancet. 2010; 376:124–136.
- Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL, Klein R: Retinopathy in diabetes. Dia Care. 2004; 27(suppl 1):s84–s87.
- The Role of Leukotriene Receptor Antagonist as an add on therapy to β2-Agonists in Acute Asthma
Abstract Views :170 |
PDF Views:0
Authors
Affiliations
1 School of Pharmaceutical Sciences, Vels University (VISTAS), Pallavaram, Tamil Nadu, IN
2 Department of Surgery, ESIC hospital, Chennai, Tamil Nadu, IN
1 School of Pharmaceutical Sciences, Vels University (VISTAS), Pallavaram, Tamil Nadu, IN
2 Department of Surgery, ESIC hospital, Chennai, Tamil Nadu, IN
Source
Research Journal of Pharmacy and Technology, Vol 12, No 4 (2019), Pagination: 1974-1978Abstract
Objective:This study was designed to determine the role of leukotriene receptor antagonist as an add on therapy to β2-agonists in acute asthma. Methods: A prospective study carried out in ESIC hospital in which the total number of 100 patients were enrolled. The study has two arms, the group A treated with salbutamol alone and the group B treated with salbutamol and montelukast. The symptomatic changes and variation in pulmonary function test (PFT), pulse rate (PR), respiratory rate (RR) were compared between both the group. The data were collected, compiled, analysed with statistical tools (SPSS – Microsoft Version 6). Results: In comparison of force expiratory volume % (FEV1 PRED) between the group A and group B, after 24 hours significant change was noticed in group B. The results of forced expiratory volume/forced vital capacity (FEV1/FVC%) shows a significant difference after 24 hours of the treatment with salbutamol in group A and salbutamol plus leukotriene receptor antagonist (Montelukast) from the baseline measurement. Base line asthma score shows p value (p = 0.58). But after 48 hours, significant change was noticed in both groups. p value was significant (p = 0.05). In group B, asthma score was significantly improved with passage of time. Conclusion: The study revealed the effectiveness of leukotriene receptor antagonist in preventing many types of aggravated asthmatic responses. Once-daily treatment with 10 mg of montelukast, as compared with β2-agonists, provided significant protection against severe broncho-constriction. Parameters strongly confirmed the role of leukotriene receptor antagonist when in addition added with β2-agonists.Keywords
Leukotriene Receptor Antagonist, Acute Asthma, β2-Agonists.References
- NHLBI Guideline 2007, pp. 11–12
- "Asthma Fact sheet N°307". WHO. November 2013. Archived from the original on June 29, 2011. Retrieved 3 March 2016. "Asthma Fact sheet N°307". WHO. November 2013. Archived from the original on June 29, 2011. Retrieved 3 March 2016.
- Laviolette, M., Malmstrom, K., Lu, S., Chervinsky, P., Pujet, J.C., Peszek, I., Zhang, J. and Reiss, T.F. (1999). Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med. 160: 1862- 1868.
- Tan TA, Spector SL. Exercise-induced asthma: diagnosis and management. Ann Allergy Asthma Immunol 2002;89:226–36.
- Inman MD, O’Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med 1996;153:65–9.
- Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. Ann Intern 2000;132:97–104.
- Kanniess, F., Richter, K., Böhme, S., Jörres, R.A. and Magnussen, H. (2002). Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J. 20: 853-858.
- National Asthma Education and Prevention Program. (1997). Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health. NIH Publication 97-4051.
- Laviolette, M., Malmstrom, K., Lu, S., Chervinsky, P., Pujet, J.C., Peszek, I., Zhang, J. and Reiss, T.F. (1999). Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med. 160: 1862-1868.
- Gauvreau, G,M., Parameswaran, K. N., Watson, R.M. and O'Byrne, P.M. (2001) Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma. Am J Respir Crit Care Med. 164: 1495-1500.
- Barnes, N.C. (2000). Effects of antileukotrienes in the treatment of asthma. Am J Respir Crit Care Med. 161: S73-S76.
- Yoshida, S., Ishizaki, Y., Shoji, T., Onuma, K., Nakagawa, H., Nakabayashi, M., Akahori, K., Hasegawa, H. and Amayasu, H. (2000). Effect of pranlukast on bronchial inflammation in patients with asthma. Clin Exp Allergy. 30: 1008-1014.
- Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet L-P, Wei LX, Efthimiadis AE, Zhang J and Hargreave FE (1999). Montelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial. EurRespir J., 14: 12-18.
- Syed hyderrazanaqvi, Mahayrukh, Farooqalamsiddiqui and asif bin rehman (2011). Role of leukotriene receptor antagonist in acute Severe attack of bronchial asthma in comparison with conventional therapy: Pakistan Journal of Pharmacology.,Vol.28, No.2, July 2011, pp.13-21.
- Carlos A. Camargo, Jr., Howard A. Smithline, Marie-Pierre Malice, Stuart A. Green, and Theodore F. Reiss (2003).A Randomized Controlled Trial of Intravenous Montelukast in Acute Asthma.Am J RespirCrit Care Med Vol 167. pp 528–533, 2003
- Malmstrom, K., Rodriguez-Gomez, G.and Guerra, J. (1999). Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial; Montelukast/Beclomethasone Study Group. Ann Intern Med. 130: 487-495.
- P. Geetha, M. Kousalya, S. Geetha Lakshmi, R. Gopi. Prescribing Pattern of Drugs Used For Respiratory Disease in Pediatric Patients at Private Hospital. Research J. Pharm. and Tech. 9(3): Mar., 2016; Page 251-256.
- A. Ramya, P. Geetha, P. Shanmugasundaram. Assessment of Appropriate use of Antibiotics in Paediatric Department of A Tertiary Care Teaching Hospital. Research J. Pharm. and Tech. 2017; 10(2): 381-384.
- Pavithra H. Dave, Preetha. Pathogenesis and Novel Drug for Treatment of Asthma – A Review. Research J. Pharm. and Tech 2016; 9(9):1519-1523.